Biotechnology News and Research

RSS

pSivida receives full payment of $15M note from Alimera Sciences

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).

29 Apr 2010

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three months ended March 31, 2010, and filed its first quarter 2010 Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Apr 2010

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Targeted Genetics Corporation announced today that its licensing partner, Celladon Corporation, has reported today that Celladon's first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

29 Apr 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. Proceeds from the second tranche will be used to continue to advance Lycera's discovery and development efforts and further support the growth of the company.

29 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Adolor's ENTEREG first-quarter net product sales increases to $5.3 million

Adolor Corporation today reported a net loss of $9.6 million, or $(0.21) per basic and diluted share, for the three months ended March 31, 2010, compared to a net loss of $13.2 million, or $(0.28) per basic and diluted share, for the three months ended March 31, 2009.

29 Apr 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $8.6 million, or $0.19 per share compared with a net loss of $19.7 million, or $0.51 per share, for the same period in 2009.

29 Apr 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.

29 Apr 2010

Goodwin Biotechnology, Hyprocell sign collaborative agreement to strengthen clinical development services

Goodwin Biotechnology Inc., a full service contract biomanufacturing company, and Hyprocell LLC, a clinical cell line development services company, jointly announced today their collaborative agreement to create a business model enabling customers to access their one stop shop services.

28 Apr 2010

Many Americans aren't taking necessary steps to protect against diabetes: Study

Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention. However, while nearly 60 percent of Americans are concerned about developing diabetes, many aren't taking the necessary steps to protect their health, according to a recent study by the International Diabetes Center and Abbott.

28 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

Kaiser Permanente approves over 250 grants and donations totaling $7 million

Kaiser Permanente, one of America's leading health care providers and nonprofit health plans, announced today it approved more than 250 grants and donations nationwide totaling approximately $7 million in the first quarter of 2010. The grants focused on expanding access to nutritious food, providing safe spaces for all ages to increase physical activity, increasing opportunities for continuing education, and eliminating health disparities.

28 Apr 2010

CTI receives positive reception from EMEA clinical experts for pixantrone MAA

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

28 Apr 2010

IMB awards manufacturer licenses to PPD’s Athlone facility

PPD, Inc. today announced its contract research facility in Athlone, Ireland, has been awarded manufacturer licenses by the Irish Medicines Board. The licenses support investigational medicinal products and marketed products and provide laboratory certifications for quality control of medicinal products.

28 Apr 2010

Pepscan reaches partnering agreement for therapeutic vaccine portfolio with Immunovo

Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.

28 Apr 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

Transplanted pig cells may bring relief from insulin injections in type I diabetics

Living Cell Technologies, a New Zealand based biotechnology company that is investigating the use of living pig cells in the treatment of diabetes has now received $700,000 (US$500,000) grant from the Juvenile Diabetes Research Foundation International for further human trials.

28 Apr 2010

Study results from US Military Malaria Vaccine Program announced

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that the US Military Malaria Vaccine Program presented results of its study using the Biojector2000 with a recombinant DNA vaccine at two recent conferences. A Cooperative Research and Development Agreement was signed with the Navy in April 2009 to work together on the study.

28 Apr 2010

Shire receives Paragraph IV Notice Letter from Anchen over filing of ANDA for generic INTUNIV

Shire plc, the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter from Anchen Pharmaceuticals, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 1 mg, 2 mg, 3 mg, and 4 mg guanfacine hydrochloride extended release tablets, INTUNIV(TM).

28 Apr 2010

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Biotechnology News and Research

pSivida receives full payment of $15M note from Alimera Sciences

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Adolor's ENTEREG first-quarter net product sales increases to $5.3 million

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Goodwin Biotechnology, Hyprocell sign collaborative agreement to strengthen clinical development services

Many Americans aren't taking necessary steps to protect against diabetes: Study

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Kaiser Permanente approves over 250 grants and donations totaling $7 million

CTI receives positive reception from EMEA clinical experts for pixantrone MAA

IMB awards manufacturer licenses to PPD’s Athlone facility

Pepscan reaches partnering agreement for therapeutic vaccine portfolio with Immunovo

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Transplanted pig cells may bring relief from insulin injections in type I diabetics

Study results from US Military Malaria Vaccine Program announced

Shire receives Paragraph IV Notice Letter from Anchen over filing of ANDA for generic INTUNIV

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News